Jean-Marc Allaire – M.D., Co-founder & CEO
Jean-Marc served as senior Director and then V.P. European operations at Idenix Pharmaceuticals, based in Montpellier, where he initiated and developed Idenix activities from 2000 to 2010. Before that he was Scientific Attaché at the French Embassy in Washington DC. He started his career in clinical research (infectious disease and lung disease) in Abbott Diagnostics (HIV and HCV diagnostic kits: 1989-1990), Hoechst Marion Roussel (immunostimulant and anti asthmatic drug candidates: 1990-1994) and from 1994 to 1999 in Pierre-Fabre as Therapeutic Division Director (anti asthmatic and antibiotic drug candidates, antiviral vaccine candidate). Jean-Marc graduated from Paris Medical school (M.D. 1986), Institut Pasteur Paris (virology, immunology, 1988 &1989) and EMLyon business school (AMP 2010).
Stéphane Salamone – Ph.D., Chemistry Director
Stéphane is Director of Chemistry at Oxeltis since October 2020. He joined Oxeltis in 2014 as Research Scientist and had progressively increasing responsibilities. His experience at Oxeltis includes work on several nucleoside, pronucleotide, macrocyclic and heterocyclic drug candidates in medchem programs for Oxeltis’ clients. Stéphane was previously in Aarhus University (DK), working on the synthesis of novel iminosugars as galactosidase inhibitors and the development of a new glycosyl ester for chemical glycosylation. Formerly at Pasteur Institute of Paris he worked on the preparation of oligosaccharides for the design of a glycoconjugate synthetic vaccine against Shigella flexneri. Stéphane holds a Ph.D. in organic chemistry (2010) from Nancy University for his work on the development of a new route to L-iduronic acid derivatives (Sanofi-Aventis funding). Stéphane is coauthor of 12 publications and 1 patent.
Christophe Parsy – Ph.D., MBA, Business & Strategic Development Director
With over 25 years in pharma across CROs, biotech, and large pharma, Christophe brings deep expertise in anti-infectives (HIV, HCV…) antimicrobials, oncology, and small molecule chemistry. He contributed to clinical candidates like IDX320, Samatasvir, and Uprifosbuvir. His skills span small molecules, prodrugs, DNA-encoded libraries, AI-driven design, FBDD, and targeted protein degradation. As Head of Medicinal Chemistry and Senior Leader of Integrated Drug Discovery at Oncodesign Services, he managed preclinical projects and led strategic alliances, due diligence, external collaborations and promoting the company’s integrated discovery capabilities globally. Now, as Business & Strategic Development Director at Oxeltis, he combines scientific depth with strategic insight to build strong client partnerships, identify new opportunities, and guide company positioning. By aligning Oxeltis’s scientific capabilities with client and industry needs, Christophe is instrumental in driving innovation-led growth, expanding global visibility, and reinforcing the company’s role as a trusted partner in early-stage drug discovery—particularly in small molecules, targeted protein degradation, and complex nucleoside/nucleotide chemistry.